8-K filing — Spero Therapeutics, Inc. (SPRO)
Filed: 2026-08-28 AccNo: 0001193125-26-374788 Size: 148 KB Item 1.01: Entry into a Material Definitive Agreement Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits
Stocks · News reference
Spero Therapeutics Announces $105M In Non-Recourse Non-Dilutive Royalty Financing With KKR's Healthcare Royalty
Financing supports Phase 2 development of SP001, Spero’s first immunology drug candidate, in-licensed from Innovent BiologicsTransaction unlocks immediate value from future Utebzi (tebipenem pivoxil) milestones and
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Spero Therapeutics Files Prospectus To Offer Up To $300M In Securities
-SEC Filing
Spero Therapeutics Q2 EPS $(0.16) Down From $(0.03) YoY
Spero Therapeutics shares are trading lower. The company announced an exclusive license agreement with Innovent Biologics for SP001, a third‑gen Fc‑silent anti‑CD40L antibody.